@dzif.bsky.social🇫🇷🤝🇩🇪 New funding for #HIV and #hepatitis cure research! #DZIF and #ANRSMIE are launching a €2 million joint call to support Franco-German teams working towards durable HIV remission and a functional cure for hepatitis B and D.
📅 Apply from Oct 26, 2026 to Jan 12, 2027
👉 Read more: t1p.de/3u52g
@dzif.bsky.social🌟 Introducing the DZIF Rising Star Award! For the first time, the #DZIF and #DZIFAcademy are recognizing outstanding early-career scientists in translational infection research with a €2,500 prize.
📅 Apply by October 31, 2026!
@dzif.bsky.social🦠 #INCATE, co-founded by #DZIF, awards Swiss start-up #PhalconBio €250,000 to advance preclinical development of an inhaled phage therapy for ventilator-associated pneumonia.
👉 Read more: t1p.de/0agp5
@dzif.bsky.social🦠 A clearer picture of microbial communities: Metax, a new taxonomic profiler developed at #HZI with #DZIF scientists, improves the reliable detection of microbial signatures.
👉 Read more: t1p.de/jjnqy
@dzif.bsky.socialA new way to target drug-resistant #tuberculosis: An international team including #DZIF scientists has shown how the natural compound #corramycin targets DNA gyrase and why it remains effective against fluoroquinolone-resistant bacteria.
👉 Read more: t1p.de/t7m2a
@dzif.bsky.social@dzif.bsky.socialHow can personalized #phage therapy be applied safely and consistently in clinical practice? A new #guideline covers key aspects like phage selection, quality control and clinical use. 👉 t1p.de/kocwc
@dgfi-org.bsky.social #DZIF @awmf.bsky.social @uniklinikkoeln.bsky.social @goetheuni.bsky.social